Bansk Group has completed a continuation fund transaction to support the next stage of growth at Arcadia Consumer Healthcare, extending its partnership with the consumer health platform it first backed in 2021.

The deal was co-led by Coller Capital and Ares secondaries funds, with additional support from investors including BlackRock, Churchill, Dextra Partners, and Future Standard. The transaction offered existing Bansk investors a liquidity option while bringing in new capital to fund further expansion.

Arcadia owns a portfolio of over-the-counter medicines, vitamins, and nutritional supplements, including brands such as Colace, Senokot, Nizoral, and CloSYS. Since Bansk’s initial investment, the company has executed multiple organic growth initiatives and completed two acquisitions.

“Arcadia’s trajectory over the past four years reflects Bansk’s strategy in action – partnering with great consumer businesses and helping them scale with discipline, innovation, and a deep commitment to the end consumer,” said Chris Kelly, senior partner at Bansk.

Bart Becht, senior partner and chairman of Bansk, said the continuation fund structure enabled the firm to provide liquidity while maintaining exposure to what it sees as a long-term growth platform.

Chief executive Mike DeBiasi said the additional capital would support Arcadia’s ambition to build a differentiated portfolio of consumer healthcare brands and accelerate innovation across its product range.

The transaction highlights continued private equity reliance on continuation vehicles as a tool to balance investor liquidity with conviction in scaled consumer assets.

If you think we missed any important news, please do not hesitate to contact us at [email protected].

Can`t stop reading? Read more.